We are excited to announce that Imagion Biosystems (ASX: IBX) will be attending two premier medical conferences this fall: the Radiological Society of North America (RSNA) Annual Meeting and the San Antonio Breast Cancer Symposium (SABCS).
RSNA Annual Meeting
November 30 – December 4, 2025 | Chicago, IL
RSNA brings together the world’s largest gathering of radiologists, imaging companies, and medical professionals advancing the field of diagnostic imaging. Our team will be in Chicago to connect with the radiology community and discuss strategic partnership opportunities in the emerging molecular MRI space.
As we continue developing MagSense® technology, we are eager to engage with radiologists and imaging professionals interested in learning how molecular MRI could enhance cancer detection capabilities, as well as strategic partners exploring opportunities in this new market.
San Antonio Breast Cancer Symposium
December 9-12, 2025 | San Antonio, TX
SABCS is the world’s leading conference focused on the state of the art in breast cancer diagnosis, treatment, and prevention. As we prepare to launch our Phase II clinical trials for HER2+ breast cancer, this conference represents an important opportunity to expand our network of leading breast cancer specialists and researchers.
We are looking forward to connecting with oncologists, breast cancer specialists, and potential clinical trial sites to discuss our upcoming Phase II study and the role of molecular MRI in advancing early breast cancer detection.
Who Is Attending
Executive Chairman Bob Proulx and Chief Business Officer Ward Detwiler will be at both RSNA and SABCS, and our Wayne State University collaborator Dr. E. Mark Haacke will also be in attendance at RSNA. Our team is available for meetings throughout both conferences to discuss MagSense® technology, clinical development, and partnership opportunities.
Let’s Connect
If you are attending either RSNA or SABCS and would like to meet with our team, we would love to connect. Whether you are interested in the clinical applications of MagSense®, exploring partnership opportunities in molecular MRI, or learning more about our Phase II trial plans, reach out to schedule time with us.
We look forward to meaningful conversations about the future of cancer detection and the role of molecular MRI in transforming early diagnosis.
Find Time to Connect
